Jumpei Teramachi

Okayama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Mutual amplification of sensory nerve outgrowth and tumor progression in myeloma.

Mutual amplification of sensory nerve outgrowth and tumor progression in myeloma.

Journal: Haematologica

Published: November 27, 2025

Angiogenin-induced Osteoclastogenesis Mediates Bone Destruction in Oral Squamous Carcinoma.

Angiogenin-induced Osteoclastogenesis Mediates Bone Destruction in Oral Squamous Carcinoma.

Journal: Anticancer research

Published: January 25, 2025

Myeloma cell growth suppression by osteoblast-derived extracellular vesicles: the creation of a non-permissive niche for myeloma cells by bone-forming osteoblasts.

Myeloma cell growth suppression by osteoblast-derived extracellular vesicles: the creation of a non-permissive niche for myeloma cells by bone-forming osteoblasts.

Journal: Haematologica

Published: September 03, 2024

Exacerbation of diabetes due to F. Nucleatum LPS-induced SGLT2 overexpression in the renal proximal tubular epithelial cells.

Exacerbation of diabetes due to F. Nucleatum LPS-induced SGLT2 overexpression in the renal proximal tubular epithelial cells.

Journal: BMC nephrology

Published: August 04, 2024

Elotuzumab-mediated ADCC with Th1-like Vγ9Vδ2 T cells to disrupt myeloma-osteoclast interaction.

Elotuzumab-mediated ADCC with Th1-like Vγ9Vδ2 T cells to disrupt myeloma-osteoclast interaction.

Journal: Cancer science

Published: June 04, 2024

Inflammatory Cytokine-Induced Muscle Atrophy and Weakness Can Be Ameliorated by an Inhibition of TGF-β-Activated Kinase-1.

Inflammatory Cytokine-Induced Muscle Atrophy and Weakness Can Be Ameliorated by an Inhibition of TGF-β-Activated Kinase-1.

Journal: International journal of molecular sciences

Published: April 28, 2024

Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid.

Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid.

Journal: International journal of hematology

Published: November 22, 2023

Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.

Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.

Journal: International journal of hematology

Published: August 12, 2023

Therapeutic efficacy of the resorcylic acid lactone LL-Z1640-2 for adult T-cell leukaemia/lymphoma.

Therapeutic efficacy of the resorcylic acid lactone LL-Z1640-2 for adult T-cell leukaemia/lymphoma.

Journal: EJHaem

Published: May 31, 2023

Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors.

Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors.

Journal: International journal of hematology

Published: January 04, 2023

Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents.

Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents.

Journal: Journal of bone and mineral metabolism

Published: January 03, 2023

The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2.

The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2.

Journal: Antioxidants (Basel, Switzerland)

Published: December 20, 2022

Showing 1-12 of 49

Last Updated: 09/26/2026